CHRU Jean Minjoz
CHRU Jean Minjoz
Besançon, France11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cancer, disease susceptibility, inherited disease susceptibility, neoplasm | Recruiting | Not applicable | 2026-04-03 | NCT04141462 | |
| CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-03-27 | NCT05260528 | |
| Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine | cancer, neoplasm | Recruiting | Phase 2 | 2025-09-22 | NCT04614480 | |
| LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, agranulocytosis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hematologic disorder, intestinal disorder, leukocyte disorder, leukopenia, neoplasm, neutropenia, rectal disorder | Active, not recruiting | Phase 2 | 2025-08-19 | NCT04166604 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT03806309 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 | |
| SCAD : a Registry of Spontaneous Coronary Artery Dissection | idiopathic spontaneous coronary artery dissection | Recruiting | Not stated | 2024-10-29 | NCT06601270 | |
| Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Not stated | 2024-02-21 | NCT03022188 | |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment | Immunotherapy | Active, not recruiting | Phase 2 | 2024-02-13 | NCT04169841 |